Skip to content
Head to head

Axsome Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: AXSM · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

AXSM -11.1%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
AXSMVRTX
Snapshot
Sector--Biotechnology
Last price129.36515.02
Change today-4.66%-1.08%
1-year return-9.7%+22.0%
Market cap$6.80B$130.58B
52-week range123.00 – 260.19412.27 – 568.67
Valuation
P/E (TTM)-42.6933.14
P/E percentile, own 5-yr range10th99th
P/B64.556.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.6815.32
Net profit (TTM)$-193.57M$3.88B
Revenue (TTM)$865.27M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+51.9%+11.8%
Gross margin93.2%85.5%
Operating margin-18.9%33.1%
Net margin-18.2%30.7%
Free cash flow (TTM)$-82.61M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership91.6%96.8%
Insider activity (12mo)21 buy / 29 sell28 buy / 22 sell
Short interest (% of float)6.2%1.9%
Analyst consensus94% buy / 6% hold (17)95% buy / 5% hold (21)
Analyst price target$264 (+104%)$624 (+21%)
StockVane view
StockVane Quant RatingD (27)C (68)
Company
Employees9256,400
Founded20121989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.